Epigenetic Therapies

表观遗传学 医学 计算生物学 生物 遗传学 基因
作者
Wallace Bourgeois,Scott A. Armstrong,Emily Heikamp
出处
期刊:Cold Spring Harbor Perspectives in Medicine [Cold Spring Harbor Laboratory Press]
卷期号:16 (3): a041637-a041637 被引量:9
标识
DOI:10.1101/cshperspect.a041637
摘要

Epigenetic therapies are emerging for pediatric cancers. Due to the relatively low mutational burden in pediatric tumors, epigenetic dysregulation and differentiation blockade is a hallmark of oncogenesis in some childhood cancers. By targeting epigenetic regulators that maintain tumor cells in a primitive developmental state, epigenetic therapies may induce differentiation. The most well-studied and clinically advanced epigenetic-targeted therapies include azacitidine and decitabine, which inhibit DNA methylation through competitive inhibition of the enzymatic activity of the DNA methyltransferase family enzymes. These DNA hypomethylating agents are Food and Drug Administration (FDA) approved for hematologic malignancies. The discovery that DNA hypermethylation occurs in patients with isocitrate dehydrogenase (IDH) mutations has led to the development and FDA approval of IDH inhibitors for hematologic and solid tumors. Epigenetic dysregulation in pediatric tumors is also driven by changes in the "histone code" that either promote oncogene expression or repress tumor suppressors. Cancers whose chromatin landscape is characterized by such aberrant histone posttranslational modifications may be amenable to targeted therapies that inhibit the chromatin-modifying enzymes that read, write, and erase these histone modifications. Small molecules that inhibit the enzymatic activity of histone deacetylases, acetyltransferases, and methyltransferases have been approved for the treatment of some adult cancers, and these agents are currently under investigation in various pediatric tumors. Chromatin regulatory complexes can be hijacked by oncogenic fusion proteins that are produced by chromosomal translocations, which are common drivers in pediatric cancer. Small molecules that disrupt oncogenic fusion protein activity and their associated chromatin complexes have demonstrated remarkable promise, and this approach has become the standard treatment for a subset of leukemias driven by the PML-RARA oncogenic fusion protein. A deeper understanding of the mechanisms that drive epigenetic dysregulation in pediatric cancer may hold the key to future success in this field, as the landscape of druggable epigenetic targets is also expanding.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丁亦竹发布了新的文献求助100
刚刚
能干灯泡发布了新的文献求助10
1秒前
赘婿的应助被观山青采纳,获得10
1秒前
传奇3的应助被平常的路人采纳,获得10
1秒前
我家电脑完成签到 ,获得积分10
2秒前
3秒前
科目三的应助被XPR采纳,获得10
3秒前
eeeee完成签到,获得积分10
4秒前
木子发布了新的文献求助10
5秒前
7秒前
memebao完成签到,获得积分10
8秒前
瑶瑶完成签到,获得积分10
9秒前
yyy完成签到,获得积分10
11秒前
lv完成签到,获得积分10
11秒前
12秒前
12秒前
圆圈完成签到,获得积分10
12秒前
Abracadabra的应助被wwwwwl采纳,获得10
13秒前
KK完成签到,获得积分10
14秒前
15秒前
代迪完成签到,获得积分10
15秒前
超级无敌的应助被lv采纳,获得10
16秒前
17秒前
17秒前
不喝水的鱼完成签到,获得积分10
18秒前
18秒前
FreedomThh完成签到,获得积分10
18秒前
哇啦发布了新的文献求助10
18秒前
沐木完成签到,获得积分10
20秒前
20秒前
研友_8WbVOZ完成签到,获得积分10
21秒前
pp完成签到,获得积分10
21秒前
XPR发布了新的文献求助10
21秒前
星辰大海的应助被阿白采纳,获得10
21秒前
ad完成签到,获得积分20
22秒前
zheng-homes发布了新的文献求助30
22秒前
是我呀吼发布了新的文献求助10
23秒前
充电宝的应助被XPR采纳,获得10
24秒前
CJJ完成签到,获得积分10
25秒前
王小玮完成签到,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181767
求助须知:如何正确求助?哪些是违规求助? 9571480
关于积分的说明 21818225
捐赠科研通 7778030
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479598